dc.contributor.author | Uygur, Meliha Melin | |
dc.contributor.author | Villanova, Marta | |
dc.contributor.author | Frara, Stefano | |
dc.contributor.author | Giustina, Andrea | |
dc.date.accessioned | 2024-06-12T07:07:42Z | |
dc.date.available | 2024-06-12T07:07:42Z | |
dc.date.issued | 2024 | en_US |
dc.identifier.citation | Uygur, M. M., Villanova, M., Frara, S., & Giustina, A. (2024). Clinical Pharmacology of Oral Octreotide Capsules for the Treatment of Acromegaly. TouchREVIEWS in endocrinology, 20(1), 37–42. https://doi.org/10.17925/EE.2024.20.1.9 | en_US |
dc.identifier.issn | 2752-5457 | |
dc.identifier.uri | https://doi.org/10.17925/EE.2024.20.1.9 | |
dc.identifier.uri | https://hdl.handle.net/11436/9083 | |
dc.description.abstract | The primary goal of acromegaly treatment is to normalize biochemical parameters as it significantly reduces the risks of complications and comorbidities associated with the disease. First-line medical treatment is commonly represented by injectable somatostatin analogues (SRLs) after surgery. In June 2020, with the integration of Transient Permeation Enhancer® technology, oral octreotide capsules (OOCs) received regulatory approval from the US Food and Drug Administration for long-term maintenance treatment in patients with acromegaly who have responded to and tolerated treatment with octreotide or lanreotide. We reviewed the clinical pharmacological data on the development and clinical use of OOCs. The pharmacokinetic and pharmacodynamic data on OOCs showed a dose–dependent increase in octreotide levels and remarkable suppression of growth hormone secretion. The efficacy and safety of OOCs were investigated in four clinical trials conducted on patients with complete or partially controlled acromegaly. The trials resulted in the maintenance of biochemical control after switching from injectable SRLs to OOCs, with a comparable side-effect profile. Moreover, the acromegaly symptoms improved in patients on OOC. The data showed a patient preference to continue in the OOC arm for the extension phase of the trials. From the clinical pharmacological perspective, oral formulation of octreotide has the advantage of efficacy and safety with respect to injectable octreotide. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Touch Briefings | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Acromegaly | en_US |
dc.subject | Efficacy | en_US |
dc.subject | Injectable somatostatin ligands | en_US |
dc.subject | Oral octreotide capsules (OOC) | en_US |
dc.subject | Patient adherence | en_US |
dc.subject | Pituitary Tumor Centers of Excellence (PTCOE) | en_US |
dc.subject | Quality of life | en_US |
dc.subject | Somatostatin analogues | en_US |
dc.subject | Therapy | en_US |
dc.title | Clinical pharmacology of oral octreotide capsules for the treatment of acromegaly | en_US |
dc.type | article | en_US |
dc.contributor.department | RTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
dc.contributor.institutionauthor | Uygur, Meliha Melin | |
dc.identifier.doi | 10.17925/EE.2024.20.1.9 | en_US |
dc.identifier.volume | 20 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.startpage | 37 | en_US |
dc.identifier.endpage | 42 | en_US |
dc.relation.journal | touchREVIEWS in Endocrinology | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |